SARS-CoV-2 导致的 CD4 T 细胞应答受损：癌症合并 COVID-19 患者使用 PD-1 阻断的理由？
Impaired CD4 T-cell Response to SARS-CoV-2: Rationale for PD-1 Blockade in Patients with Cancer and COVID-19?
机构信息
Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Cancer Discov. 2021 Aug;11(8):1877-1878. doi: 10.1158/2159-8290.CD-21-0613.
PMID:34344757
Abstract
Cancer is a strong risk factor for severe COVID-19 disease. In this issue of , Bilich and colleagues demonstrate impaired preexisting and newly generated CD4 T-cell response to SARS-CoV-2 in patients with cancer..
摘要
癌症是导致严重 COVID-19 疾病的一个重要危险因素。在本期 中，Bilich 及其同事证明了癌症患者对 SARS-CoV-2 的预先存在和新产生的 CD4 T 细胞反应受损。
Zotero 插件